COMP <GO>
MNPR vs KMDA // EV/EBITDA & P/E VALUATION
Monopar Therapeutics Inc. (NASDAQ) VS. Kamada Ltd. (NASDAQ) • 15-METRIC TALLY: MNPR 1
— KMDA 1
■ METRIC PARITY
LAST: $71.91 (-2.02%) • MKT CAP: $482.7M
valuation
—
LAST: $7.95 (-0.62%) • MKT CAP: $458.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNPR VS. KMDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MNPR | KMDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.53% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.4 | 42.9 | -9.42 | KMDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $482.7M | $458.8M | $23.9M | MNPR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MNPR REV | KMDA REV | MNPR GROSS % | KMDA GROSS % | MNPR FCF | KMDA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$12.2M | — |
| FY 2024 | $0 | — | — | — | -$6.4M | — |
| FY 2023 | $0 | — | — | — | -$7.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNPR // BETA —
KMDA // BETA —